Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development; Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways; and Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33. Zura Bio Limited was founded in 2021 and is based in Henderson, Nevada.

Zura Bio Limited

Zura Bio ( ($ZURA) ) just unveiled an update. On March 19, 2026, Zura Bio reported its full-year 2025 results, highlighting progress in two ongoing...

Zura Bio Reports 2025 Results, Extends Cash Runway Outlook

The latest announcement is out from Zura Bio ( ($ZURA) ). On March 10, 2026, Zura Bio Ltd., a clinical-stage biotechnology company developing thera...

Current Quarter	$-0.17	Next Quarter	$-0.16
Current Year	$-0.63	Next Year	$-0.61
QoQ Growth	+5.9%	YoY Growth	+3.2%
3Y EPS CAGR	N/A	Target Price	$15.86
Consensus	Buy	Upside	+177.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ZURA	$5.72	+1.24%	528.33K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ZURA	$5.72	+1.2%	528.33K
3
4
5
6

ZURA

ZURA

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Zura Bio Limited Data in Excel

Get Zura Bio Limited Data in Excel